Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a $257 million Series D financing co--led by investment funds managed by BlackRock and Eclipse, ...

Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, ...

Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the ...

Cellares, an Integrated Development and Manufacturing Organization (IDMO), announced a $257 million Series D financing co‑led ...

Raw materials play a critical role in cell therapy manufacturing. Choosing suboptimal materials at any stage of development ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.

Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

MaxCyte and Ori Biotech entered into a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. The collaboration combines the MaxCyte ...